• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM
Click for more information
6.56% 28.5¢

IMMUTEP LIMITED - Announcements

Market Cap $486.6M  ! watchlist Created with Sketch. Add to my watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMM2013 AGM CEO AddressPRICE SENSITIVE15/11/13
IMMUpdate on CVac Clinical Development ProgramPRICE SENSITIVE11/11/13
IMMFirst Quarter Conference Call Transcript11/11/13
IMMSupplemental Information for Quarterly Conference Call07/11/13
IMMPrima and Neopharm enter into licence for CVac in IsraelPRICE SENSITIVE06/11/13
IMMFirst Quarter Highlights & Conference Call01/11/13
IMMAppendix 4C - quarterlyPRICE SENSITIVE31/10/13
IMMAnnual Report on Form 20-F filed with SEC31/10/13
IMMAnnual Report to shareholders14/10/13
IMMNotice of Annual General Meeting/Proxy Form14/10/13
IMMChange of Director's Interest Notice10/10/13
IMMChange of Director's Interest Notice09/10/13
IMMChange of Director's Interest Notice03/10/13
IMMTranscript of Management Presentation on CVac Phase 2 Trial03/10/13
IMMSupplemental information to management presentation01/10/13
IMMManagement Presentation of CVac Phase 2 Trial Results01/10/13
IMMTop-line Analysis of CVac Phase 2 TrialPRICE SENSITIVE18/09/13
IMMPrima to present at 1st Global Life Sciences Conference11/09/13
IMMPrima to present to Society for Immunotherapy of Cancer04/09/13
IMMAppendix 4E & 2013 Full Year Statutory AccountsPRICE SENSITIVE30/08/13
IMMPrima Files US Shelf Registration Statement29/08/13
IMMPrima to Present at Global Investment Conference21/08/13
IMMCleansing Notice & Appendix 3B15/08/13
IMMApproval received to start CANVAS clinical trials in KoreaPRICE SENSITIVE14/08/13
IMMCleansing Notice & Appendix 3B08/08/13
IMMFourth Quarter Conference Call Transcript08/08/13
IMMSupplemental Information for Quarterly Conference Call06/08/13
IMMFourth Quarter Highlights and Conference Call26/07/13
IMMAppendix 4C - quarterlyPRICE SENSITIVE26/07/13
IMMCleansing Notice & Appendix 3B19/07/13
IMMResponse to ASX Price QueryPRICE SENSITIVE11/07/13
IMMChange of Director's Interest Notice05/07/13
IMMNew clinical trial sites activated in Europe for CANVASPRICE SENSITIVE04/07/13
IMMNew Phase 2 Clinical Programs for CVacPRICE SENSITIVE25/06/13
IMMTrading Halt Request24/06/13
IMMTrading HaltPRICE SENSITIVE24/06/13
IMMChange of Director's Interest Notice19/06/13
IMMChange of Director's Interest Notice19/06/13
IMMChange of Director's Interest Notice19/06/13
IMMCAN-003 to be presented at European Cancer Congress19/06/13
IMMOptions - Top 20 and distribution schedule18/06/13
IMMCompletion of Entitlement Offer13/06/13
IMMPrima Newsletter13/06/13
IMMChange of Director's Interest Notice27/05/13
IMMMailing of Prospectus and Entitlement and Acceptance Form24/05/13
IMMPrima to present at Marcum LLP Microcap Conference20/05/13
IMMChange of Director's Interest Notice20/05/13
IMMChange of Director's Interest Notice20/05/13
IMMChange of Director's Interest Notice20/05/13
IMMChange of Director's Interest Notice20/05/13
IMMChange of Director's Interest Notice20/05/13
IMMCleansing Statement & Appendix 3BPRICE SENSITIVE17/05/13
IMMResults of Meeting16/05/13
IMMEGM 2013 Chairman's Address16/05/13
IMMCompletion of SPPPRICE SENSITIVE15/05/13
IMMEntitlement Offer Letter to Shareholders14/05/13
IMMEntitlement Offer Prospectus & Appendix 3BPRICE SENSITIVE13/05/13
IMMAppendix 3X08/05/13
IMMDirector Appointment08/05/13
IMMPrima Newsletter03/05/13
IMMPrima Presentation at ISCT Annual Meeting24/04/13
IMMSupplemental Information for Quarterly Conference Call24/04/13
IMMPRIMA BIOMED UPDATES CLINICAL LEADERSHIP TEAM24/04/13
IMMPRIMA BIOMED QUARTERLY RESULTS AND CONFERENCE CALLPRICE SENSITIVE19/04/13
IMMJAPANESE PATENT GRANTED FOR CVACPRICE SENSITIVE17/04/13
IMMChange of Director's Interest Notice12/04/13
IMMChange of Director's Interest Notice11/04/13
IMMNotice under ASIC CO 09/42511/04/13
IMMNotice of Extraordinary General Meeting/Proxy Form11/04/13
IMMShare Purchase Plan Offer Documents11/04/13
IMMChange of Director's Interest Notice10/04/13
IMMShare Purchase Plan UpdatePRICE SENSITIVE09/04/13
IMMChange in Senior Management28/03/13
IMM3.8 MILLION EURO GRANT TO SUPPORT CVAC DEVELOPMENTPRICE SENSITIVE20/03/13
IMMPrima BioMed to Present at ISBioTech Annual Meeting11/03/13
IMMPrima BioMed Conference Call Transcript08/03/13
IMMSupplemental Information for Prima BioMed Conference Call06/03/13
IMMPrima Biomed Conference Call05/03/13
IMMPrima Biomed commences CANVAS Clinical Trial in EuropePRICE SENSITIVE28/02/13
IMMPrima Newsletter26/02/13
IMMHalf Yearly Report and AccountsPRICE SENSITIVE22/02/13
IMMAppendix 3B21/02/13
IMMPrima receives $1.4m R&D Tax Incentive rebatePRICE SENSITIVE06/02/13
IMMInvestor Presentation February 201304/02/13
IMMPrima presents at ISCT annual meeting04/02/13
IMMPrima to present at BIO CEO & Investor Conference29/01/13
IMMPrima BioMed to host investor days in Australia24/01/13
IMMAppendix 4C - quarterlyPRICE SENSITIVE23/01/13
IMMAnnouncement from Martin Rogers24/12/12
IMMAppendix 3Y24/12/12
IMMAppendix 3B16/11/12
IMMResults of Meeting16/11/12
IMM2012 AGM CEO Address16/11/12
IMM2012 AGM Chairman Address16/11/12
IMMCAN-003 INTERIM ANALYSIS PRESENTATION15/11/12
IMMTeleconference details for 2012 Annual General Meeting14/11/12
IMMINTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIALPRICE SENSITIVE14/11/12
IMMAppendix 4C - quarterlyPRICE SENSITIVE26/10/12
IMMManagement Reorganisation26/10/12
IMMPRR to present at conference in Hong Kong18/10/12
IMM2013 AGM CEO Address
15/11/13PRICE SENSITIVE
IMMUpdate on CVac Clinical Development Program
11/11/13PRICE SENSITIVE
IMMFirst Quarter Conference Call Transcript
11/11/13
IMMSupplemental Information for Quarterly Conference Call
07/11/13
IMMPrima and Neopharm enter into licence for CVac in Israel
06/11/13PRICE SENSITIVE
IMMFirst Quarter Highlights & Conference Call
01/11/13
IMMAppendix 4C - quarterly
31/10/13PRICE SENSITIVE
IMMAnnual Report on Form 20-F filed with SEC
31/10/13
IMMAnnual Report to shareholders
14/10/13
IMMNotice of Annual General Meeting/Proxy Form
14/10/13
IMMChange of Director's Interest Notice
10/10/13
IMMChange of Director's Interest Notice
09/10/13
IMMChange of Director's Interest Notice
03/10/13
IMMTranscript of Management Presentation on CVac Phase 2 Trial
03/10/13
IMMSupplemental information to management presentation
01/10/13
IMMManagement Presentation of CVac Phase 2 Trial Results
01/10/13
IMMTop-line Analysis of CVac Phase 2 Trial
18/09/13PRICE SENSITIVE
IMMPrima to present at 1st Global Life Sciences Conference
11/09/13
IMMPrima to present to Society for Immunotherapy of Cancer
04/09/13
IMMAppendix 4E & 2013 Full Year Statutory Accounts
30/08/13PRICE SENSITIVE
IMMPrima Files US Shelf Registration Statement
29/08/13
IMMPrima to Present at Global Investment Conference
21/08/13
IMMCleansing Notice & Appendix 3B
15/08/13
IMMApproval received to start CANVAS clinical trials in Korea
14/08/13PRICE SENSITIVE
IMMCleansing Notice & Appendix 3B
08/08/13
IMMFourth Quarter Conference Call Transcript
08/08/13
IMMSupplemental Information for Quarterly Conference Call
06/08/13
IMMFourth Quarter Highlights and Conference Call
26/07/13
IMMAppendix 4C - quarterly
26/07/13PRICE SENSITIVE
IMMCleansing Notice & Appendix 3B
19/07/13
IMMResponse to ASX Price Query
11/07/13PRICE SENSITIVE
IMMChange of Director's Interest Notice
05/07/13
IMMNew clinical trial sites activated in Europe for CANVAS
04/07/13PRICE SENSITIVE
IMMNew Phase 2 Clinical Programs for CVac
25/06/13PRICE SENSITIVE
IMMTrading Halt Request
24/06/13
IMMTrading Halt
24/06/13PRICE SENSITIVE
IMMChange of Director's Interest Notice
19/06/13
IMMChange of Director's Interest Notice
19/06/13
IMMChange of Director's Interest Notice
19/06/13
IMMCAN-003 to be presented at European Cancer Congress
19/06/13
IMMOptions - Top 20 and distribution schedule
18/06/13
IMMCompletion of Entitlement Offer
13/06/13
IMMPrima Newsletter
13/06/13
IMMChange of Director's Interest Notice
27/05/13
IMMMailing of Prospectus and Entitlement and Acceptance Form
24/05/13
IMMPrima to present at Marcum LLP Microcap Conference
20/05/13
IMMChange of Director's Interest Notice
20/05/13
IMMChange of Director's Interest Notice
20/05/13
IMMChange of Director's Interest Notice
20/05/13
IMMChange of Director's Interest Notice
20/05/13
IMMChange of Director's Interest Notice
20/05/13
IMMCleansing Statement & Appendix 3B
17/05/13PRICE SENSITIVE
IMMResults of Meeting
16/05/13
IMMEGM 2013 Chairman's Address
16/05/13
IMMCompletion of SPP
15/05/13PRICE SENSITIVE
IMMEntitlement Offer Letter to Shareholders
14/05/13
IMMEntitlement Offer Prospectus & Appendix 3B
13/05/13PRICE SENSITIVE
IMMAppendix 3X
08/05/13
IMMDirector Appointment
08/05/13
IMMPrima Newsletter
03/05/13
IMMPrima Presentation at ISCT Annual Meeting
24/04/13
IMMSupplemental Information for Quarterly Conference Call
24/04/13
IMMPRIMA BIOMED UPDATES CLINICAL LEADERSHIP TEAM
24/04/13
IMMPRIMA BIOMED QUARTERLY RESULTS AND CONFERENCE CALL
19/04/13PRICE SENSITIVE
IMMJAPANESE PATENT GRANTED FOR CVAC
17/04/13PRICE SENSITIVE
IMMChange of Director's Interest Notice
12/04/13
IMMChange of Director's Interest Notice
11/04/13
IMMNotice under ASIC CO 09/425
11/04/13
IMMNotice of Extraordinary General Meeting/Proxy Form
11/04/13
IMMShare Purchase Plan Offer Documents
11/04/13
IMMChange of Director's Interest Notice
10/04/13
IMMShare Purchase Plan Update
09/04/13PRICE SENSITIVE
IMMChange in Senior Management
28/03/13
IMM3.8 MILLION EURO GRANT TO SUPPORT CVAC DEVELOPMENT
20/03/13PRICE SENSITIVE
IMMPrima BioMed to Present at ISBioTech Annual Meeting
11/03/13
IMMPrima BioMed Conference Call Transcript
08/03/13
IMMSupplemental Information for Prima BioMed Conference Call
06/03/13
IMMPrima Biomed Conference Call
05/03/13
IMMPrima Biomed commences CANVAS Clinical Trial in Europe
28/02/13PRICE SENSITIVE
IMMPrima Newsletter
26/02/13
IMMHalf Yearly Report and Accounts
22/02/13PRICE SENSITIVE
IMMAppendix 3B
21/02/13
IMMPrima receives $1.4m R&D Tax Incentive rebate
06/02/13PRICE SENSITIVE
IMMInvestor Presentation February 2013
04/02/13
IMMPrima presents at ISCT annual meeting
04/02/13
IMMPrima to present at BIO CEO & Investor Conference
29/01/13
IMMPrima BioMed to host investor days in Australia
24/01/13
IMMAppendix 4C - quarterly
23/01/13PRICE SENSITIVE
IMMAnnouncement from Martin Rogers
24/12/12
IMMAppendix 3Y
24/12/12
IMMAppendix 3B
16/11/12
IMMResults of Meeting
16/11/12
IMM2012 AGM CEO Address
16/11/12
IMM2012 AGM Chairman Address
16/11/12
IMMCAN-003 INTERIM ANALYSIS PRESENTATION
15/11/12
IMMTeleconference details for 2012 Annual General Meeting
14/11/12
IMMINTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIAL
14/11/12PRICE SENSITIVE
IMMAppendix 4C - quarterly
26/10/12PRICE SENSITIVE
IMMManagement Reorganisation
26/10/12
IMMPRR to present at conference in Hong Kong
18/10/12
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
28.5¢ 		Change
-0.020(6.56%) 		Mkt cap ! $486.6M
Open High Low Value Volume
30.5¢ 30.5¢ 28.5¢ $913.3K 3.099M

Buyers (Bids)

No. Vol. Price($)
6 124895 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
29.0¢ 30287 2
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
28.5¢ 		  Change
-0.020 ( 6.80 %)
Open High Low Volume
30.5¢ 30.5¢ 28.5¢ 1420446
Last updated 15.59pm 21/11/2024 ?
IMM (ASX) Chart

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.